Insmed INSM
NASDAQ INSM
$126.29 -0.39 (-0.31%)
At close: Sep 4, 2026 · 4:00 PM EDT

Insmed (INSM) Other Non Operating Income (2013 - 2026)

Insmed (INSM) posted Other Non Operating Income of -$531000.0 for Q2 2026, up 27.85% on a QoQ basis from -$736000.0 in Q1 2026, and down 217.22% year-over-year from $453000.0 in Q2 2025.

Analysis

Insmed (INSM) Other Non Operating Income (2013 - 2026) Analysis & Trends

Insmed has reported Other Non Operating Income for 14 years, with the latest figure at -$531000.0 in Q2 2026.

  • On a quarterly basis, Other Non Operating Income fell 217.22% year-over-year to -$531000.0 in Q2 2026; TTM through Jun 2026 was -$3.7 million, a 54.07% decrease from a year earlier, with the FY2025 full-year figure at -$1.8 million, down 680.08% from the prior year.
  • Other Non Operating Income was -$531000.0 for Q2 2026 at Insmed, up from -$736000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $3.5 million in Q4 2023, with the low at -$4.3 million in Q2 2022.
  • Average Other Non Operating Income over 5 years is -$412611.1, with a median of -$567000.0 recorded in 2025.
  • The sharpest annual moves came in 2022 and 2024: Other Non Operating Income plunged 2804.65% in 2022, then surged 254.08% in 2024.
  • Over 5 years, Other Non Operating Income stood at $1.1 million in 2022, then soared by 210.27% to $3.5 million in 2023, then slumped by 75.19% to $870000.0 in 2024, then slumped by 309.54% to -$1.8 million in 2025, then soared by 70.87% to -$531000.0 in 2026.
  • The last three Other Non Operating Income figures came in at -$531000.0 (Q2 2026), -$736000.0 (Q1 2026), and -$1.8 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -531,000.00
Mar 31, 2026 -736,000.00
Dec 31, 2025 -1.82 Mn
Sep 30, 2025 -603,000.00
Jun 30, 2025 453,000.00
Mar 31, 2025 132,000.00
Dec 31, 2024 870,000.00
Sep 30, 2024 -3.85 Mn
Jun 30, 2024 384,000.00
Mar 31, 2024 2.36 Mn
Dec 31, 2023 3.51 Mn
Sep 30, 2023 -1.30 Mn
Jun 30, 2023 1.18 Mn
Mar 31, 2023 -1.53 Mn
Dec 31, 2022 1.13 Mn
Sep 30, 2022 -1.51 Mn
Jun 30, 2022 -4.31 Mn
Mar 31, 2022 -1.25 Mn
Sep 30, 2021 -476,000.00
Jun 30, 2021 -17.69 Mn